{"url":"https://newsforagent.com/news/2026-11-03/cellkey-ai-omicspharm-marketplace-launch","markdown_url":"https://newsforagent.com/news/2026-11-03/cellkey-ai-omicspharm-marketplace-launch.md","title":"CellKey AI Launches OmicsPharm Marketplace for Omics Services","headline":"CellKey AI Launches OmicsPharm, an Omics Marketplace With AI Agent Data Interpretation","description":"CellKey AI launched OmicsPharm, an omics marketplace combining bioanalytical services with AI Agent interpretation, after serving over 100 clients.","section":"Product Launches","published_at":"2026-11-03T07:58:50+00:00","modified_at":"2026-11-03T07:58:50+00:00","author":"News Desk","key_takeaways":["CellKey AI launched OmicsPharm, a marketplace for genomics, transcriptomics, proteomics, metabolomics, ADC analysis and multi-omics services.","CellKey AI has provided more than 1,000 analytical services to over 100 clients to date.","CellKey AI is running a proof of concept with Kyoto University's Center for iPS Cell Research and Application (CiRA) in Japan."],"companies":[{"name":"CellKey","is_primary":true,"profile_url":"https://akta.pro/company-profiles/000cogo/cellkey","website":"http://cellkey.co.kr"}],"source":{"publisher":"PRLog","title":"CELLKEY AI Officially Launches Omics Marketplace 'OmicsPharm'","url":"https://www.prlog.org/13180772-cellkey-ai-officially-launches-omics-marketplace-omicspharm.html"},"other_sources":[{"publisher":"PR Newswire","url":"https://www.prnewswire.com/news-releases/perturbai-and-openai-unveil-first-of-its-kind-ai-reasoning-agents-to-scale-biomedical-discovery-302914929.html"},{"publisher":"FinancialContent Business Page","url":"https://www.financialcontent.com/article/getnews-2026-10-21-creative-biolabs-advances-single-cell-and-single-nucleus-rna-sequencing-solutions-for-complex-tissue-research"}],"tags":["Product Launches","CellKey"],"body_markdown":"CellKey AI has launched OmicsPharm, an omics marketplace that combines bioanalytical services with AI Agent-based data interpretation for researchers and companies. The South Korean company announced the platform on November 3, 2026, according to [PRLog](https://www.prlog.org/13180772-cellkey-ai-officially-launches-omics-marketplace-omicspharm.html).\n\n## What OmicsPharm Offers Researchers\n\n[CellKey](https://akta.pro/company-profiles/000cogo/cellkey)'s OmicsPharm brings genomics, transcriptomics, proteomics, metabolomics, biopharmaceutical characterization, antibody-drug conjugate (ADC) analysis and integrated multi-omics analysis onto a single platform. The company pairs a network of analytical partners with AI Agents to connect data generation, interpretation, visualization and application.\n\nIn conventional bio-research workflows, finding analytical service providers, comparing quotes, managing experiments, receiving results, interpreting data and preparing reports are often handled separately. OmicsPharm is designed to let researchers select services suited to their objectives and manage both the analysis process and the resulting data in one place.\n\nA key component is the platform's Agentic AI architecture, which CellKey AI plans to use to improve AI Agent performance based on data accumulated through the analysis process. The platform is being structured to connect analytical service execution with data accumulation, normalization, quality assessment and ongoing Agent performance improvement.\n\nCellKey AI said it has provided more than 1,000 analytical services to over 100 clients. In Korea, the company has worked with organizations including Yuhan Corporation, LG Chem, Alteogen, Seoul National University Hospital, Severance Hospital and Samsung Medical Center. Internationally, it has conducted analytical projects with Massachusetts General Hospital (MGH), a Harvard Medical School teaching hospital, the Carver College of Medicine at the University of Iowa and Weill Cornell Medicine-Qatar. In Japan, CellKey AI is currently conducting a proof of concept (PoC) with Kyoto University's Center for iPS Cell Research and Application (CiRA).\n\n## CellKey's Funding and Platform Record\n\nCellKey was founded in May 2019 and has developed multiple proprietary AI platforms, according to akta.pro [company records](https://akta.pro/company-data). The same records list three funding rounds: a January 2021 seed round with one investor, an October 2021 round with two investors and a February 2022 seed round led by ETRIHOLDINGS. The records also note a Series A strategic investment from D&CTR to strengthen protein technology competitiveness and accelerate global expansion.\n\n## How Peers Positioned AI and Sequencing Tools\n\nPerturbAI and OpenAI unveiled AI reasoning agents on October 21, 2026 that analyzed a whole-brain genomic atlas in 32 minutes, with human experts preferring the agents' interpretations 75% of the time in blinded comparisons, [PR Newswire](https://www.prnewswire.com/news-releases/perturbai-and-openai-unveil-first-of-its-kind-ai-reasoning-agents-to-scale-biomedical-discovery-302914929.html) reported. Creative Biolabs expanded its single-cell and single-nucleus RNA sequencing platform on October 21, 2026, covering sample preparation, sequencing and bioinformatics, [FinancialContent Business Page](https://www.financialcontent.com/article/getnews-2026-10-21-creative-biolabs-advances-single-cell-and-single-nucleus-rna-sequencing-solutions-for-complex-tissue-research) reported.\n\n## CellKey's Planned Data Hub\n\nCellKey AI plans to expand OmicsPharm into an Agentic AI-based marketplace for bioanalysis and data distribution. The company aims to develop the platform into a data hub connecting the generation, normalization and interpretation of biological data for drug discovery and precision medicine.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}